Marvel Biosciences receives Australian patent allowance for MB-204 Jun 8, 2026 07:00AM
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204 Jun 8, 2026 07:00AM
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit Apr 23, 2026 07:30AM
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders Apr 16, 2026 07:00AM
Marvel Biosciences secures funding for autism drug trial from 5 Horizons Apr 7, 2026 12:26PM


Apr 7, 2026 07:30AM Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
Mar 30, 2026 07:30AM Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
Mar 25, 2026 07:30AM Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
Mar 18, 2026 07:02AM Marvel Biosciences receives US patent for autism drug candidate MB-204
Mar 18, 2026 07:00AM Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204